Skip to main content

Table 1 Standard gamble utilities (range 0 = dead 1 = health state without treatment side effects or recurrence of melanoma) for health states in our study and in Kilbridge et al. [7]

From: Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma

Scenario Scenario summary This study, n = 130 Kilbridge et al. (2001), n = 95
Mean SD Median % Missing Mean SD Median % Missing
(A) IFN-α 2b treatment without side effects Treatment involves: 1 month of daily intravenous IFN administration; 11 months of 3 self-administrations of IFN per week; medication for fever prevention; 12 blood tests. No side effects 0.94 0.14 0.99 1.5 0.92 0.15 0.98 0.0
(B) IFN-α 2b treatment with mild-to-moderate side effects Treatment as in scenario A. Side effects similar to a flu (e.g., nausea, headache, fatigue) leading to impairments such as spending a little more time resting 0.90 0.18 0.99 1.5 0.88 0.17 0.97 0.0
(C) IFN-α 2b treatment with mild-to-moderate side effects and laboratory side effects Treatment as in scenario A. Side effects as in scenario B. Serious abnormalities in blood tests leading to dose reduction and possibly to termination of treatment without reduction of effectiveness 0.88 0.20 0.99 0.8 0.86 0.20 0.94 0.0
(D) IFN-α 2b treatment with severe side effects Treatment as in scenario A. Side effects as in scenario B, but with at least one episode of severe side effects similar to a bad flu (e.g., very high fever, frequent vomiting, depression and suicidal ideation) leading to impairments such as inability to do even light chores. Dose reduction and possibly termination of treatment without reduction of effectiveness 0.81 0.25 0.90 0.0 0.81 0.25 0.90 0.0
(E) Recurrence and death from melanoma after previous IFN-α 2b treatment Recurrence of melanoma after having completed 12 month treatment. Symptoms lead to impairment such as spending a little more time resting. Later, symptoms increase progressively, leading to death from melanoma 0.60 0.32 0.50 1.5 0.62 0.34 0.71 0.0
(F) Recurrence and death from melanoma without previous IFN-α 2b treatment As in scenario E, but without having received previous treatment for melanoma 0.60 0.31 0.50 2.3 0.61 0.34 0.67 0.0
  1. IFN-α 2b interferon alfa-2b, SD standard deviation